Company intelligence / Profile preview

Zaurac Healthcare

Stockholm, Sweden

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Zaurac Healthcare is a clinical-stage biotechnology company based in Stockholm, Sweden, dedicated to developing transformative therapies for rare metabolic and neurological diseases. The company's lead candidate, ZRC-101, is an oral small molecule inhibitor of glycolate oxidase (HAO1) currently being evaluated in Phase 2 clinical trials for the treatment of Primary Hyperoxaluria (PH). By inhibiting the production of oxalate, ZRC-101 aims to prevent kidney damage and systemic oxalosis in patients with PH1, PH2, and PH3. Zaurac leverages a lean development model and is part of the Esmaeilzadeh Holding (EHAB) portfolio, focusing on orphan indications with high unmet medical needs.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zaurac Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zaurac Healthcare.

Explore the full profile